Topline results from the Phase II/III LIFT-AD clinical trial of Athira Pharma, Inc.’s hepatocyte growth factor (HGF) modulator fosgonimeton in mild-to-moderate Alzheimer’s disease show the drug did not achieve statistical significance across any of the study’s primary or secondary endpoints. The company did not shut down development of the drug, but after three mid-stage trial failures, the asset may have reached the end of the road.
Athira’s Fosgonimeton Fails In Phase II/III LIFT-AD Trial, Future Uncertain
Phase I Next-Gen Drug May Become Priority
The company said that while its drug did not achieve statistical significance on any endpoints in the Alzheimer’s study, improvements favoring fosgonimeton showed potential for HGF modulation.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.